Flashcards on Ovarian Stimulation in IVF
Ovarian Stimulation in IVF: A Student's Comprehensive Guide
Tap to flip · Swipe to navigate
Ovarian stimulation drugs & management
56 cards
Card 1
Question: Name three follitropin alfa biosimilars mentioned and their manufacturers.
Answer: Bemfola (Gedeon Richter); Ovaleap (Theramex); Afolia/Primapur (Gedeon Richter, limited markets).
Card 2
Question: What evidence supports using follitropin alfa biosimilars in practice?
Answer: Regulator approval based on comparability data (PK/PD and clinical bridging). RCTs (Strowitzki 2016, Rettenbacher 2015) showed equivalent oocyte yield
Card 3
Question: How should embryologists treat the distinction between originator and biosimilar FSH in cycle records?
Answer: Recording originator vs biosimilar is administrative only; it is not a diagnostic or interpretive variable for embryology.
Card 4
Question: Which factors determine the starting FSH dose for ovarian stimulation?
Answer: AMH band (drives the starting-dose range), age and BMI (older age and higher BMI increase dose within the range), and prior response (strongest guide
Card 5
Question: What is the typical final daily FSH dose range stated?
Answer: Typically 100–300 IU, with rare cases needing more due to individual pharmacodynamics of receptors.
Card 6
Question: What is the practical effect of increasing FSH mid-cycle for a poor responder?
Answer: Increasing mid-stimulation rarely rescues a poor response because by day 5–6 the follicle cohort is already committed; evidence for benefit is weak.
Card 7
Question: What is the main risk of decreasing FSH in the late follicular phase?
Answer: Late-follicular reduction can narrow the cohort (cohort-narrowing risk), potentially reducing the number of recruitable follicles.
Card 8
Question: When reading a cycle record, which three numbers are diagnostically useful?
Answer: 1) Starting FSH dose (exposure that matters). 2) Days the FSH window stayed open (duration above threshold). 3) Cohort distribution at trigger (whethe
Card 9
Question: List the LH-containing products described and their source/content.
Answer: Menopur (hMG): postmenopausal urine; 75 IU FSH + 75 IU LH activity (mostly hCG) per vial. Luveris (rLH): CHO cells; 75 IU recombinant LH per vial. Per
Card 10
Question: What important note is made about the LH activity in hMG (Menopur)?
Answer: The LH activity in hMG is mostly hCG, which has a longer half-life than LH but is functionally equivalent at the receptor.